2274. Rate of all-cause hospitalization at year 2 between treatment groups following diagnosis of nontuberculous mycobacterial lung disease in the US
Session: Poster Abstract Session: Non-Tuberculous Mycobacteria - Epidemiology and Management
Saturday, October 7, 2017
Room: Poster Hall CD
Background: The study compared rates of hospitalization between treatment groups in patients with nontuberculous mycobacterial lung disease (NTMLD) in a US national managed care claims database.

Methods: Patient (N=1039) pharmacy claims at year 1 following NTMLD diagnosis were classified into 3 treatment groups including triple combo (macrolide + ethambutol + rifamycin ± other drugs) (G1), other antibiotics used by physicians for NTMLD (G2), and no treatment (G3). Hospitalization rates at year 2 were compared between treatment groups using mixed effects logistic regression to adjust for patient characteristics and comorbidities measured by Charlson Comorbidity Index (CCI) during the 12 months prior to NTMLD diagnosis (baseline).

Results: Mean age was 66, 66 and 73 years with 65%, 70% and 66% women in G1 (n=353), G2 (n=388) and G3 (n=298) respectively. At baseline, there was no difference on CCI (CCI≈2) between treatment groups. However, comorbidity distribution differed prominently in asthma (22.1%, 26.3% and 11.4%), arrhythmia (19.3%, 19.3% and 27.2%), cystic fibrosis (0.8%, 4.6% and 0%), immune disorder (7.6%, 9% and 2.7%), pneumonia (49.0%, 41.8% and 32.6%), and tuberculosis (9.3%, 8.2% and 5.4%), and in immunosuppressant use (51%, 51.5% and 25.2%). Baseline hospitalization was 31.7% in G1, 33.0% in G2, and 25.8% in G3. At year 2, CCI stayed almost unchanged from the baseline scores (1.9 in G1, 2.0 in G2, and 1.9 in G3). Unadjusted hospitalization rates were 19.6%, 27.8% vs 20.8%, and adjusted rates were 44.5%, 56.1% and 47.8% in 3 groups respectively (Figure). G2 had a 60% increase in risk of hospitalization after adjustment (odds ratio (OR)=1.60, 95% CI: 1.11-2.29, p=0.01) compared to G1 but no statistically significant difference compared to G3 (OR=1.40, p=0.08). Cerebrovascular disease (OR=1.8, p<0.02), COPD (OR=1.60, p<0.01), cystic fibrosis (OR=5.85, p<0.01), depression (OR=1.64, p<0.05), and other lung disease (OR=1.42, p<0.05) were associated with a higher risk of hospitalization at year 2 after NTMLD diagnosis.

Conclusion: We observed a lower hospitalization rate in NTMLD patients receiving antibiotics that were concordant with first line ATS/IDSA guidelines recommendations in comparison with those who used other antibiotic regimens.

Theodore Marras, MD1, Mehdi Mirsaeidi, MD, MPH2, Engels Chou, MS3, Gina Eagle, MD3, Raymond Zhang, MBA4, Ping Wang, PhD3 and Quanwu Zhang, PhD3, (1)Toronto Western Hospital, Toronto, ON, Canada, (2)University of Miami, Miami, FL, (3)Insmed Incorporated, Bridgewater, NJ, (4)Orbis Data Solutions, Woburn, MA


T. Marras, None

M. Mirsaeidi, None

E. Chou, Insmed Incorporated: Employee , Salary

G. Eagle, Insmed Incorporated: Employee , Salary

R. Zhang, Insmed Incorporated: Consultant , Consulting fee

P. Wang, Insmed Incorporated: Employee , Salary

Q. Zhang, Insmed Incorporated: Employee , Salary

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.